LITTLE KNOWN FACTS ABOUT RAS-IN-2.

Participant has experienced almost every other prior or concurrent malignancy inside two years ahead of enrollment with the following exceptions: sufficiently treated localized basal mobile or squamous mobile carcinoma, or curatively dealt with in situ carcinoma of your cervix or breast. Other exceptions might be regarded upon sponsor session.“Th